Sees FY23 revenue up 5%-7%, consensus $13.64B. The company said, "The company estimates net sales growth for the full year 2023, versus the prior year period, to be in a range of approximately 5 to 7 percent on a reported basis, and approximately 6 to 8 percent on an organic basis. Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $1.11 to $1.21 and estimates adjusted EPS, excluding certain charges (credits) of $1.86 to $1.93."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BSX:
- BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2022
- Notable companies reporting before tomorrow’s open
- Citi Says Market Upside Appears Limited, but These 2 Stocks Have More Room to Run
- Boston Scientific put volume heavy and directionally bearish
- Boston Scientific targeting ‘double digit’ EPS growth in 2023, consensus $1.93